CURASIGHT - Key Persons
Job Titles:
- Board Member, CSO and Co - Founder ( 2013 )
Education and experience: Born 1963, MD, PhD, DMSc, MBA and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark.
His research is focused on molecular imaging with PET and PET/MRI and theranostics in cancer.
His achievements include development of several new tracers that have reached first-in-humans clinical use.
He is the holder of an ERC Advanced Grant, has published more than 500 peer-review articles and has received numerous prestigious scientific awards over the years.
He is a member of the Danish Academy of Technical Sciences.
Job Titles:
- Co - Founder of Curasight a / S
Andreas Kjæris co-founder of Curasight A/S, CSO and member of the Board of Directors of the company. From the University of Copenhagen, he has obtained an MD, PhD, DMSc and an MBA for Copenhagen Business School. He is a professor at University of Copenhagen and a chief physician at Rigshospitalet, and head of Cluster for Molecular Imaging His research is focused on molecular imaging with PET, PET/MRI and theranostics in cancer. He has published more than 500 peer-reviewed articles, has received numerous scientific awards and is the holder of an ERC Advanced Grant. He is also a member of the Danish Academy of Technical Sciences, which is a non-profit organization that strives to make Denmark a leading region within Science & Engineering.
Job Titles:
- Member of the Board
- Member of the Board of Directors of Curasight a / S
Charlotte Vedel has been a member of the Board of Directors of Curasight A/S since 2020. She holds an M.Sc. and Ph.D. in Biotechnology from DTU and M.Sc. in Biomedicine, immunology and haematology from Ulster University. She has been CTO at the Novo Nordisk Center for Biosustainability, which focuses on research in developing technologies to help facilitate the transformation from an oil-based chemical industry to a sustainable bio-based society. In 2017 she founded Lactobio, which is a company that focuses on developing microbial solutions against pathogenic and resistant bacteria relevant for skin and gut health.
Job Titles:
- CDO
- CHIEF DEVELOPMENT OFFICER
- Founder
Hanne is founder and part-time CEO of ROS Therapeutics focused on development of a pediatric formulation of methotrexate for children with juvenile arthritis, psoriasis and ALL.
Hanne Damgaard Jensen is the Chief Development Officer (CDO) of the company. From the University of Copenhagen, she has obtained a master's degree in pharmaceutical science and an MBA from Copenhagen Business School.
Job Titles:
- State Authorised Public Accountant
Job Titles:
- Co - Founder of Curasight a / S
- Director CMC and Co - Founder ( 2013 )
Education and experience: Born 1972, PhD, M.Sc.(chemistry and radiochemistry)
Jacob Madsen is co-founder of Curasight A/S and is also Director of Chemistry, Manufacturing, Control (CMC) of the company. He holds a PhD and M.Sc. in chemistry and radiochemistry, and is also Chief Radiochemist at Rigshospitalet, Copenhagen Universal Hospital's Department of Clinical Physiology, Nuclear Medicine and PET. His main research areas are development and production of radiolabeled compounds for molecular imaging of diseases.
Kirsten Drejer holds an M.Sc. in Pharmacy and a PhD in pharmacology and is well known in the pharma and biotech community, in which she has over 30 years of experience. She is best known for being co-founder and CEO of Symphogen A/S through 18 years, but before this she also held scientific and managerial positions at Novo Nordisk. Symphogen is a biotech company with a primary focus on oncology and immuneoncology. During her time at Symphogen, she raised EUR 300m from international investors and EUR 250m through partnerships. Kirsten Drejer is also a member of the board of directors at several other biotech or pharma companies, including Zealand Pharma and Antag Therapeutics. She thus has vast experience within drug development within oncology, building biotech companies as well as raising capital.
Job Titles:
- Deputy Chairman of the Board
- Chairman of the Board of Directors of Curasight a / S
Education and experience: Born 1967, B.Sc., BBa - CBS. CDO at UNEEG medical A/S CEO of Contura International A/S (2015 - 2018) CEO of DDD-Diagnostic A/S (2009 - 2015) Lars Trolle has been Chairman of the Board of Directors of Curasight A/S since 2014 and Deputy Chairman of the Board since 2020. He holds a B.Sc. in Mechanical and Plastic Engineering from Elsinore Technical University, and a BBa in Organization and Strategy from Copenhagen Business School. In the period 2009-2015, Mr Trolle was the CEO of DDD-Diagnostic A/S, which is a developer and supplier of gamma cameras to Nuclear medicine. From 2015-2018 he was CEO of Contura International A/S, where he afterwards became Chief Development Officer & VP Operation at UNEEG medical A/S. UNEEG is a Danish company with focus on cognitive technologiesfor monitoring and analyzing brain activity. Lars Trolle on LinkedIn
Job Titles:
- Head
- Head of Quality Assurance
Nic Gillings is Head of Quality Assurance and Regulatory Affairs. He has over 25 years of experience in the field of radiopharmaceutical sciences, where his expertise primarily lies within development of new PET radiopharmaceuticals for research, diagnosis and clinical trials. Nic Gillings is also Chief Radiochemist at Rigshospitalet, the National University Hospital of Denmark in its Department of Clinicals Physiology, Nuclear Medicine and PET.
Education and experience: Born 1958, M.Sc. - DTU. Director at Novo Nordisk Foundation EVP of R&D, Novozymes (2000-2016) EVP of Novo Nordisk (1984-2000) Chairman of the Board at DTU (Technical Univ. of Denmark) Board member: Danfoss, Corbion, Cytovac and other biotech companies Per Farholt has been Chairman of the Board of Directors of Curasight A/S since 2020. Mr Farholt holds an M.Sc. in Chemical Engineering from Technical University of Denmark (DTU), where he also is Chairman of the Board. In 2010 he was appointed Honorary Professor by DTU's Institute for System Biology. Farholt started his career as a research chemist at Novo Nordisk, where he eventually rose to Executive Vice President in the period 1984-2000. Afterwards, he moved to Novozymes and became the Executive Vice President of Research & Development, where he has helped the developing of a unique industrial biotechnology platform. Furthermore, Per Falholt is a member of the Board of Directors at Danfoss, Corbion, Cytovac and other biotech companies. Per Falholt on LinkedIn
Job Titles:
- Chairman of the Board of Directors of Curasight a / S
Job Titles:
- CEO
- Board Member, CEO & CFO ( 2016 )
- CEO & CFO - Board Member
- Member of the Board of Directors of Curasight a / S
Ulrich Krasilnikoff is a member of the Board of Directors of Curasight A/S as well as being CEO and CFO of the company since 2016. He holds an MBA, Diploma Engineering and a B.Sc. in Finance and Accounting and is also a certified public accountant. In the years 2015-2016, he was Executive Vice President of BIOFAC Group which specializes in manufacturing of products for the pharmaceutical, veterinary and the nutraceutical industries. Furthermore, he has more than 10 years' experienceas partner in the private equity industry, besides he is member of the Board of Carl Hansen & Søn, Primodan, AH Metal Solutions and has previously been a member of the Board of other techcompanies.
Education and experience: Born 1967, MBA - SDU, Dipl. Ing - DTU, B.Sc. in finance and accounting - CBS, Certified Public Accountant - CBS/PWC.